Cargando…

PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis

Prostate cancer (PCa) patients are risk-stratified on the basis of clinical stage and PSA level at diagnosis and the Gleason Score (GS) in prostate biopsy. However, these parameters are not completely accurate in discriminating between high- and low-risk disease, creating a need for a reliable marke...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bravaccini, Sara, Puccetti, Maurizio, Bocchini, Martine, Ravaioli, Sara, Celli, Monica, Scarpi, Emanuela, De Giorgi, Ugo, Tumedei, Maria Maddalena, Raulli, Giandomenico, Cardinale, Loredana, Paganelli, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844862/ https://www.ncbi.nlm.nih.gov/pubmed/29523813 http://dx.doi.org/10.1038/s41598-018-22594-1

Ejemplares similares

Spotlight on PSMA as a new theranostic biomarker for bladder cancer
por: Tumedei, Maria Maddalena, et al.
Publicado: (2021)

Easily detectable cytomorphological features to evaluate during ROSE for rapid lung cancer diagnosis: from cytology to histology
por: Ravaioli, Sara, et al.
Publicado: (2016)

Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?
por: Bronte, Giuseppe, et al.
Publicado: (2018)

Predictive Role of Telomerase Activity in the Clinical Outcome of Patients with Benign Lesions of the Uterine Cervix or CIN
por: Bravaccini, Sara, et al.
Publicado: (2012)

Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?
por: Bravaccini, Sara, et al.
Publicado: (2018)

Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer
por: Maltoni, Roberta, et al.
Publicado: (2020)

Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
por: Bronte, Giuseppe, et al.
Publicado: (2018)

Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?
por: Bronte, Giuseppe, et al.
Publicado: (2019)

The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial
por: Bravaccini, Sara, et al.
Publicado: (2020)

The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects
por: Bravaccini, Sara, et al.
Publicado: (2021)

Spotlight on Ki67 as a prognostic marker in early breast cancer: all that glitters may not be gold
por: Maltoni, Roberta, et al.
Publicado: (2020)

Tumor resident microbiota and response to therapies: An insight on tissue bacterial microbiota
por: Pirini, Francesca, et al.
Publicado: (2023)

Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ
por: Farolfi, Alberto, et al.
Publicado: (2020)

(68)Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy
por: Caroli, Paola, et al.
Publicado: (2020)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Pancreatic Cancer and Cellular Senescence: Tumor Microenvironment under the Spotlight
por: Cortesi, Michela, et al.
Publicado: (2021)

Androgen receptor in breast cancer: The “5W” questions
por: Ravaioli, Sara, et al.
Publicado: (2022)

Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2019)

Cell-free DNA detected by “liquid biopsy” as a potential prognostic biomarker in early breast cancer
por: Maltoni, Roberta, et al.
Publicado: (2017)

Why the complications of COVID-19 patients differ in elderly and young cancer patients
por: Bravaccini, Sara, et al.
Publicado: (2022)

Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience
por: Palleschi, Michela, et al.
Publicado: (2020)

New Biomarkers to Predict the Evolution of In Situ Breast Cancers
por: Bravaccini, S., et al.
Publicado: (2014)

Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence
por: Rengucci, Claudia, et al.
Publicado: (2014)

ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients
por: Ravaioli, Sara, et al.
Publicado: (2020)

Circulating hsa-miR-5096 predicts (18)F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors
por: Bocchini, Martine, et al.
Publicado: (2023)

Estrogen and Androgen Receptor Inhibitors: Unexpected Allies in the Fight Against COVID-19
por: Bravaccini, Sara, et al.
Publicado: (2021)

Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab
por: Palleschi, Michela, et al.
Publicado: (2022)

Phase II Study of Dehydroepiandrosterone in Androgen Receptor‐Positive Metastatic Breast Cancer
por: Pietri, Elisabetta, et al.
Publicado: (2018)

Combining preclinical tools and models to unravel tumor complexity: Jump into the next dimension
por: Miserocchi, Giacomo, et al.
Publicado: (2023)

On the Way for Patients with Prostate Cancer to the Best Use of PSMA
por: von Eyben, Finn Edler, et al.
Publicado: (2022)

Problems for Pathologists
Publicado: (1876)

The Pathologist as Poet
por: Domen, Ronald E.
Publicado: (2016)

To be or not to be an oral pathologist
por: Ramesh, V
Publicado: (2019)

Pathologists’ Fees
Publicado: (1885)

HIMSS10 – Perspectives from a newcomer pathologist and a seasoned attendee pathologist: Pathologists should attend!
por: Carter, Alexis B., et al.
Publicado: (2010)

(177)Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: von Eyben, Finn E., et al.
Publicado: (2021)

Radiomics Analysis on [(68)Ga]Ga-PSMA-11 PET and MRI-ADC for the Prediction of Prostate Cancer ISUP Grades: Preliminary Results of the BIOPSTAGE Trial
por: Feliciani, Giacomo, et al.
Publicado: (2022)

Combining liquid biopsy and functional imaging analysis in metastatic castration‐resistant prostate cancer helps predict treatment outcome
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Review by urological pathologists improves the accuracy of Gleason grading by general pathologists
por: Nakai, Yasushi, et al.
Publicado: (2015)

Association of Clinical Pathologists
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_lc8rpp8g4gcpk8fdlkbegm7105